Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

130.21USD
22 Mar 2019
Change (% chg)

$-4.00 (-2.98%)
Prev Close
$134.21
Open
$133.86
Day's High
$134.71
Day's Low
$130.12
Volume
563,470
Avg. Vol
612,992
52-wk High
$140.76
52-wk Low
$92.57

Latest Key Developments (Source: Significant Developments)

Alexion And Zealand Pharma Announce Pact To Discover And Develop Peptide Therapies
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.ZEALAND PHARMA A/S - COLLABORATION FURTHERS ALEXION'S COMPLEMENT LEADERSHIP WITH EXPANSION INTO PEPTIDE THERAPIES.ZEALAND-AGREEMENT PROVIDES ALEXION EXCLUSIVE WORLDWIDE LICENSES FOR 1 PRECLINICAL TARGET, OPTION FOR UP TO 3 ADDITIONAL TARGETS, IN COMPLEMENT PATHWAY.ZEALAND - TO RECEIVE UPFRONT PAYMENT OF $25 MILLION & EQUITY INVESTMENT OF $15 MILLION, WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT & ROYALTY PAYMENTS.ZEALAND PHARMA A/S - WILL LEAD JOINT DISCOVERY AND RESEARCH EFFORTS THROUGH PRECLINICAL STAGE.ZEALAND PHARMA A/S - ALEXION WILL LEAD DEVELOPMENT EFFORTS BEGINNING WITH IND FILING AND PHASE 1 STUDIES.ZEALAND PHARMA A/S - FOR LEAD TARGET, AGREEMENT PROVIDES POTENTIAL FOR DEVELOPMENT-RELATED MILESTONES OF UP TO $115 MILLION.ZEALAND-FOR LEAD TARGET AGREEMENT PROVIDES UP TO $495 MILLION IN SALES-RELATED MILESTONES, POTENTIAL FOR HIGH SINGLE- TO LOW DOUBLE-DIGIT ROYALTY PAYMENTS.  Full Article

Alexion Announces Interim Data From Phase 3 Study Of Soliris In Adults With Generalized Myasthenia Gravis In Muscle & Nerve
Friday, 8 Mar 2019 

March 8 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION ANNOUNCES PUBLICATION OF INTERIM DATA FROM PHASE 3 OPEN-LABEL EXTENSION STUDY SUPPORTING LONG-TERM EFFICACY AND SAFETY OF SOLIRIS® (ECULIZUMAB) IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN MUSCLE & NERVE.ALEXION - NEW DATA SUGGEST POSITIVE IMPACT ON SUSTAINED LONG-TERM CLINICAL BENEFIT FOR ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN MUSCLE & NERVE.  Full Article

Alexion Says FDA Grants Priority Review & Accepts sBLA Of SOLIRIS As Treatment For Patients With NMOSD
Saturday, 23 Feb 2019 

Feb 22 (Reuters) - Alexion Pharmaceuticals Inc ::FDA GRANTS PRIORITY REVIEW AND ACCEPTS SBLA OF SOLIRIS® (ECULIZUMAB) AS A TREATMENT FOR PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD).ALEXION PHARMACEUTICALS INC - FDA SETS ACTION DATE OF JUNE 28, 2019.ALEXION PHARMACEUTICALS INC - FILING IN EUROPEAN UNION UNDER REVIEW, AND FILING IN JAPAN PLANNED FOR Q1 2019.  Full Article

Temasek Holdings Cuts Share Stake In Amazon.Com, Takes in Total SA
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Temasek Holdings (Private) Ltd::TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN AMAZON.COM BY 46.6 PERCENT TO 35,153 SHARES- SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD TAKES SHARE STAKE IN TOTAL SA OF 460,885 SPONSORED ADR.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN ALEXION PHARMACEUTICALS INC BY 49.7 PERCENT TO 616,630 SHARES.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF DECEMBER 31, 2018 AND COMPARED WITH PREVIOUS QUARTER ENDED AS OF SEPTEMBER 30, 2018.  Full Article

Alexion Reports Fourth Quarter And Full Year 2018 Results
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $2.14.Q4 GAAP LOSS PER SHARE $0.20.Q4 REVENUE $1.129 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.06 BILLION.Q4 EARNINGS PER SHARE ESTIMATE $1.82 -- REFINITIV IBES DATA.SEES FY 2019 GAAP EARNINGS PER SHARE $6.14 TO $7.26.SEES FY 2019 REVENUE $4.625 BILLION TO $4.7 BILLION.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $9.10 TO $9.30.ALEXION PHARMACEUTICALS - FILED U.S. & EU SUBMISSIONS FOR SOLIRIS IN NEUROMYELITIS OPTICA SPECTRUM DISORDER & ON TRACK TO FILE IN JAPAN LATER IN 2019.FY2019 EARNINGS PER SHARE VIEW $8.73, REVENUE VIEW $4.75 BILLION -- REFINITIV IBES DATA.SEES 2019 TOTAL REVENUES $4,625 TO $4,700 MILLION.SEES 2019 SOLIRIS/ULTOMIRIS REVENUES $3,970 TO $4,020 MILLION.FY2019 REVENUE VIEW $4.75 BILLION -- REFINITIV IBES DATA.  Full Article

Fortress Biotech Announces CAEL-101 Strategic Partnership With Alexion Pharmaceuticals
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH ANNOUNCES CAEL-101 STRATEGIC PARTNERSHIP WITH ALEXION PHARMACEUTICALS.FORTRESS BIOTECH INC - FORTRESS-FOUNDED CAELUM BIOSCIENCES TO RECEIVE $60 MILLION IN A STRATEGIC EQUITY INVESTMENT AND OPTION FEE.FORTRESS BIOTECH INC - ALEXION HAS OPTION TO ACQUIRE CAELUM BIOSCIENCES BASED ON PHASE 2 DATA.FORTRESS BIOTECH - UNDER TERMS ALEXION WILL ACQUIRE A MINORITY EQUITY INTEREST IN CAELUM AND AN EXCLUSIVE OPTION TO ACQUIRE REMAINING EQUITY IN CO.FORTRESS BIOTECH INC - COLLABORATION ALSO PROVIDES FOR POTENTIAL ADDITIONAL PAYMENTS OF UP TO $500 MILLION IN EVENT ALEXION EXERCISES ACQUISITION OPTION.FORTRESS BIOTECH INC - ALEXION AND CAELUM WILL COLLABORATE ON DESIGN OF ONGOING DEVELOPMENT PROGRAM FOR CAEL-101.  Full Article

Alexion, Caelum Biosciences Announce Collaboration To Develop Targeted Therapy For Light Chain Amyloidosis
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND CAELUM BIOSCIENCES ANNOUNCE COLLABORATION TO DEVELOP TARGETED THERAPY FOR LIGHT CHAIN (AL) AMYLOIDOSIS.UNDER TERMS OF AGREEMENT, ALEXION WILL ACQUIRE A MINORITY EQUITY INTEREST IN CAELUM.CAELUM TO RECEIVE UP TO $60 MILLION FOR EQUITY INVESTMENT AND OPTION FEE.ALEXION HAS OPTION TO ACQUIRE CAELUM BASED ON PHASE 2 DATA.COLLABORATION ALSO PROVIDES FOR POTENTIAL ADDITIONAL PAYMENTS OF UP TO $500 MILLION.ALEXION PHARMACEUTICALS-WILL MAKE PAYMENTS TO CAELUM TOTALING UP TO $60 MILLION, INCLUDING PURCHASE PRICE FOR EQUITY, DEVELOPMENT FUNDING PAYMENTS.CAELUM WILL BE RESPONSIBLE FOR CONDUCTING DEVELOPMENT PROGRAM THROUGH END OF PHASE 2 AND FOR MANUFACTURING CAEL-101.ALEXION AND CAELUM WILL COLLABORATE ON DESIGN OF ONGOING DEVELOPMENT PROGRAM FOR CAEL-101.  Full Article

Alexion Announces Positive Top-Line Results From Phase 3 Study Of Ultomiris
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ULTOMIRIS™ (RAVULIZUMAB-CWVZ) IN COMPLEMENT INHIBITOR-NAÏVE PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS).ALEXION PHARMACEUTICALS INC - STUDY MET PRIMARY OBJECTIVE OF COMPLETE THROMBOTIC MICROANGIOPATHY (TMA) RESPONSE.ALEXION PHARMACEUTICALS INC - REGULATORY SUBMISSION IN U.S. PLANNED FOR FIRST HALF OF 2019, FOLLOWED BY EUROPEAN UNION AND JAPAN.ALEXION PHARMACEUTICALS - IN CRITICALLY ILL PATIENTS, THERE WERE 4 PATIENT DEATHS, NONE OF WHICH CONSIDERED RELATED TO TREATMENT WITH ULTOMIRIS.  Full Article

Alexion Receives Early FDA Approval For Ultomiris In Adults With Paroxysmal Nocturnal Hemoglobinuria
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION RECEIVES EARLY FDA APPROVAL FOR ULTOMIRIS™ (RAVULIZUMAB-CWVZ) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).ALEXION PHARMA - REGULATORY AUTHORITIES IN EU, JAPAN HAVE ACCEPTED & ARE REVIEWING APPLICATIONS FOR ULTOMIRIS APPROVAL AS TREATMENT FOR ADULTS WITH PNH.  Full Article

FDA Releases Label On Its Website For Alexion Pharmaceuticals' Ultomiris
Friday, 21 Dec 2018 

Dec 21 (Reuters) - U.S. Food and Drug Administration::U.S. FDA RELEASES LABEL ON ITS WEBSITE FOR ALEXION PHARMACEUTICALS' ULTOMIRIS.U.S. FDA - ULTOMIRIS IS A COMPLEMENT INHIBITOR INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.U.S. FDA - WARNS THAT LIFE-THREATENING MENINGOCOCCAL INFECTIONS HAVE OCCURRED IN PATIENTS TREATED WITH ULTOMIRIS.  Full Article

Alexion wins early U.S. approval for rare blood disorder drug

The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant market position.